Medical Devices

Promising results for bladder cancer therapy TARA-002, key FDA designations, and a $198M cash runway position Protara for a pivotal year.

A new campaign by Palvella Therapeutics and key partners aims to educate and empower patients with a rare disease, a strategic move ahead of a potential new drug.

A new drug targeting the root cause of deadly device infections enters a pivotal trial, offering hope to millions and challenging a $20 billion problem.

Eledon's tegoprubart gets Orphan Drug status, signaling a new era for liver transplant patients by potentially replacing toxic, decades-old therapies.

A $12.2M impairment charge pushed Ultralife to a net loss, but rising sales, a soaring backlog, and new efficiencies tell a far more positive story.

With its CAR-T therapy achieving franchise profitability and treating 10,000 patients, Legend Biotech eyes overall profit and next-gen cancer treatments.

Promising clinical trial results for Insulet's fully closed-loop system aim to revolutionize daily management for millions with Type 2 diabetes.

A groundbreaking analysis quantifies the hidden costs of common IV failures, showing how early detection technology can save lives and boost hospital margins.

Middle and high schoolers are building AI to aid surgery and streamline recycling, signaling a major shift from college prep to real-world innovation.

Celebrating 80 years, Aveeno renews its foundational ties with Mayo Clinic, launching a new era of oat science research for compromised skin.

Edgewise Therapeutics' drug sevasemten shows unprecedented functional stability in Becker muscular dystrophy, a pivotal shift for a disease with no treatments.

After selling assets and raising cash, Q32 Bio focuses all its resources on bempikibart, a novel drug for hair loss, with pivotal data due in 2026.

A global consortium pioneers new drugs designed specifically for children, moving away from harsh adult treatments for aggressive pediatric cancers.

ViruSure's new GMP-validated test using Oxford Nanopore sequencing promises to slash drug safety testing times, boosting supply chain resilience.

A new study reveals Canadians lost billions in wages waiting for care. This is the staggering personal and economic cost of the nation's healthcare queues.

K-pop sensation Kim Sejeong is the new face of REJURAN, a move merging celebrity appeal with advanced skin science to expand K-beauty's global reach.

A new report projects the telehealth market will skyrocket to over $2 trillion by 2034, signaling a seismic shift in how we receive medical care.

After 15 years without new therapies, Tonix Pharma's TONMYA enters the fibromyalgia market with a unique sublingual drug and an ambitious commercial plan.

Relmada Therapeutics stock skyrockets on promising bladder cancer data and a $160M financing deal, setting a high-stakes stage for its investor conference.

AEON Biopharma hires a seasoned CFO to navigate FDA trials and financial hurdles as it aims to launch its BOTOX biosimilar into a lucrative market.